← Every company
Editas Medicine Inc Patents
What Editas Medicine Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
EDIT on carbonthat →Filings on file
53
Granted
0
Still pending
53
Filed under
3 names
53 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)C12N 15/11, C12N 15/1138, C12N2310/20, A61P 3/06, C12N 9/226, A61K 31/7105, A61K 38/465, C12N 15/63, C12N 15/88, C12N 15/907, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/335, C12N2310/351, C12N2310/531, C12N2320/11, C12N2310/344, C12N2310/3521Filed as Editas Medicine, Inc.2026-02-17Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as EDITAS MEDICINE, INC.2026-01-15PAUL JOSEPH WRIGHTON | pending |
| SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESA61K 48/005, C12N 5/0647, C12N2310/20, A61P 7/06, C12N 9/226, A61K 35/28, A61K 38/00, C07K 14/805, C12N 15/111, C12N 15/1138, C12N2310/315, C12N2310/321, C12N2510/00Filed as EDITAS MEDICINE, INC.2025-12-08KaiHsin CHANG | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-12-01Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-12-01Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING FL1-1 EXPRESSIONA61K 48/005, C12N 15/1135, C12N2310/20, A61P 35/00, A61K 40/11, C12N 9/226, C07K 14/4705, C07K 14/7051, C12N 5/0636, C12N 9/22, C12N 15/111, C12N 15/63, C12N2310/3519, C12N2310/531Filed as EDITAS MEDICINE, INC.2025-11-24Aaron WILSON | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING CD70 EXPRESSIONA61K 48/005, C12N 15/1138, C12N2310/20, A61P 35/00, C12N 9/226, A61K 48/00, C07K 14/7051, C12N 5/0636, C12N 15/102, C12N 15/111, C12N 15/85, C12N2310/531, C12N2510/00Filed as Editas Medicine, Inc.2025-11-24Aaron WILSON | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING PTPN2 EXPRESSIONA61K 48/005, C12N 15/1137, C12N2310/20, A61P 35/00, C12N 9/226, A61K 48/00, C07K 14/7051, C12N 5/0636, C12N 9/16, C12N 9/22, C12N 15/102, C12N 15/111, C12N 15/85, C12N2310/3519, C12N2310/531, C12N2320/33, C12N2510/00, C12Y 301/03048Filed as EDITAS MEDICINE, INC.2025-11-24Aaron WILSON | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-11-19Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3)Filed as EDITAS MEDICINE, INC.2025-11-07PAUL JOSEPH WRIGHTON | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-11-05Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-11-05Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-10-06Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-10-06Paul Joseph Wrighton | pending |
| CRISPR CAS-RELATED METHODS AND COMPOSITIONS TARGETING PTPN2 EXPRESSIONFiled as EDITAS MEDICINE, INC.2025-09-18GEORGIA GIANNOUKOS | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc2025-08-29Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-08-29Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND ISOLATED HUMAN HEMATOPOIETIC STEM CELLS PRODUCED THEREBYC12N 15/907, A61K 47/549, Y02A 50/30, C12N 9/226, A61K 38/465, A61K 48/005, C12N 9/22, C12N 9/96, C12N 15/11, C12N 15/8216, C12N 15/85, C12N 15/902, C12N2310/3513, C12N2320/33, C12Y 301/00Filed as Editas Medicine, Inc.2025-06-18Alexandra GLUCKSMANN | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-05-22Paul Joseph Wrighton | pending |
| METHODS FOR TREATING CEP290 ASSOCIATED DISEASEC12N 9/226, C12N2310/20, A61P 27/02, C12N 15/111, C12N 15/86, C12N2750/14143Filed as EDITAS MEDICINE, INC.2025-05-16Swati MUKHERJEE | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-05-13Paul Joseph Wrighton | pending |
| CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher SyndromeC12N 9/226, C12N 9/22, C12N2310/20, A01K 67/0275, A01K2207/15, A01K2217/072, A01K2227/105, A01K2267/0306, A61K 9/0019, A61K 48/0016, C12N 15/113, C12N 15/1138, C12N 15/86, C12N2320/33, C12N2750/14143, C12Y 301/01Filed as Editas Medicine, Inc.2025-05-12Eric A. Pierce | pending |
| CRISPR-CPF1-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPYA61P 35/00, C12N 5/0636, C12N 15/11, C12N2310/20, A61P 35/02, A61K 40/31, A61K 40/11, C12N 9/226, A61K 35/17, A61K 48/005, C07K 14/7051, C12N 9/22, C12N 15/102, C12N 15/113, C12N 15/1138, C12N 15/86, C12N 15/87, C12N 15/907, C12N2310/10, C12N2320/32, C12N2510/00, C12N2740/15041, C12N2800/80Filed as EDITAS MEDICINE, INC.2025-05-06Gordon Grant Welstead | pending |
| CRISPR/RNA-GUIDED NUCLEASE RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMAFiled as EDITAS MEDICINE, INC.2025-04-04PAUL JOSEPH WRIGHTON | pending |
| MODIFIED GUIDE RNAsFiled as EDITAS MEDICINE, INC.2025-02-02PAUL JOSEPH WRIGHTON | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LIPOPROTEIN (A) EXPRESSIONFiled as EDITAS MEDICINE, INC.2025-02-02PAUL JOSEPH WRIGHTON | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3)Filed as EDITAS MEDICINE, INC.2025-02-02Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR)Filed as Editas Medicine, Inc.2025-01-15Paul Joseph Wrighton | pending |
| COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIRA61K 48/0066, C12N 15/111, C12N2310/20, C12N 9/222, A61K 48/0083, A61K 48/0091, C07K 19/00, C07K2319/20, C07K2319/80, C07K2319/85, C12N 9/22, C12N 15/113, C12N 15/625, C12N 15/64Filed as Editas Medicine, Inc.2024-12-11Cecilia Cotta-Ramusino | pending |
| CAS12A NICKASE PROTEINS AND USES THEREOFFiled as EDITAS MEDICINE, INC.2024-11-15BENJAMIN A. DINER | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LIPOPROTEIN (A) EXPRESSIONFiled as EDITAS MEDICINE, INC.2024-11-08Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3)Filed as EDITAS MEDICINE, INC.2024-11-08Paul Joseph Wrighton | pending |
| GENOME EDITING OF CELLSC12N 15/907, C12N2310/20, C12N 9/222, A61K 48/005, C12N 5/0636, C12N 9/22, C12N 15/111, C12N 15/85, C12N2510/00, C12N2750/14143, C12N2840/203Filed as Editas Medicine, Inc.2024-11-07John Anthony Zuris | pending |
| GENOME EDITING OF B CELLSC12N 15/907, C12N2310/20, C12N 9/222, A61K 35/17, C12N 5/0635, C12N 9/22, C12N 15/111, C12N 15/86, C12N2510/00, C12N2750/14143, C12N2800/22Filed as Editas Medicine, Inc.2024-11-07John Anthony Zuris | pending |
| SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESC12N 9/22, C12N 15/111, C12N2310/20, C12N 9/226, A61K 35/28, C12N 5/0647, C12N 15/102, C12N 15/113, C12N 15/907, C12N2310/315, C12N2510/00Filed as EDITAS MEDICINE, INC.2024-09-23Jennifer Leah GORI | pending |
| CRISPR Cas-Related Methods and Compositions Targeting PTPN2 ExpressionFiled as EDITAS MEDICINE, INC.2024-09-18Georgia Giannoukos | pending |
| COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASEA61P 27/02, A61K 48/0058, A61K 48/0008, A61K 48/0066, A61K 48/0091Filed as EDITAS MEDICINE, INC.2024-09-12Morgan Lee MAEDER | pending |
| SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESC12N 15/113, C12N2310/20, A61P 7/00, A61K 40/30, C12N 9/222, A61K 9/0009, A61K 31/7088, A61K 48/00, A61K2121/00, A61K2300/00, C12N 9/22, C12N 15/102, C12N 15/85, C12N2310/313, C12N2310/315, C12N2310/321, C12N2310/3521Filed as EDITAS MEDICINE, INC.2024-07-03Jennifer Leah GORI | pending |
| SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESC12N 15/113, C12N 15/907, C12N2310/20, C12N 9/226, C12N 15/11, C12N2310/10, C12N2800/80Filed as EDITAS MEDICINE, INC.2024-06-18Edouard AUPEPIN DE LAMOTHE-DREUZY | pending |
| SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESFiled as EDITAS MEDICINE, INC.2024-06-07KAIHSIN CHANG | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING FL1-1 EXPRESSIONFiled as EDITAS MEDICINE, INC.2024-05-24AARON WILSON | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING PTPN2 EXPRESSIONFiled as EDITAS MEDICINE, INC.2024-05-24AARON WILSON | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING CD70 EXPRESSIONFiled as EDITAS MEDICINE, INC.2024-05-24AARON WILSON | pending |
| ENGINEERED CRISPR/CAS12A EFFECTOR PROTEINS, AND USES THEREOFA61K 48/005, C12N 9/22, C12N2310/20, C12R2001/01, C12N 9/226, C12N 9/80, C12N 15/11, C12N 15/86, C12N2750/14143, C12Y 305/04001, C12Y 305/04002Filed as Editas Medicine, Inc.2024-05-23John Anthony Zuris | pending |
| SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESFiled as EDITAS MEDICINE, INC.2024-05-13KaiHsin CHANG | pending |
| CRISPR/RNA-GUIDED NUCLEASE RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMAFiled as EDITAS MEDICINE, INC.2024-05-06Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LIPOPROTEIN (A) EXPRESSIONFiled as EDITAS MEDICINE, INC.2024-05-06Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LIPOPROTEIN (A) EXPRESSIONFiled as Editas Medicine, Inc.2024-04-08Paul Joseph Wrighton | pending |
| CRISPR/RNA-GUIDED NUCLEASE RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMAFiled as EDITAS MEDICINE, INC.2024-04-05Paul Joseph Wrighton | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LIPOPROTEIN (A) EXPRESSIONFiled as EDITAS MEDICINE, INC.2024-02-23Paul Joseph Wrighton | pending |
| TREATMENT OF PAINA61K 35/30, C12N 15/86, C12N2310/20, A61P 1/00, C12N 9/226, A61K 31/7105, A61K 38/465, C12N 15/11, C12N 15/1138, C12N 15/90, C12N 15/907, C12N2320/11, C12N2320/32, C12N2330/51, C12N2750/14143Filed as Editas Medicine, Inc.2024-02-15Christopher Wilson | pending |
| SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESA61K 31/7088, A61K 35/28, A61K 48/00, C12N2310/20, A61P 7/06, C12N 9/226, C12N 9/22, C12N 15/11, C12N 15/113, C12N 15/87, C12N 15/907, C12N2310/315, C12N2310/3519, C12N2310/321, C12N2310/3521Filed as EDITAS MEDICINE, INC.2024-02-02KaiHsin CHANG | pending |
| CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LIPOPROTEIN (A) EXPRESSIONFiled as EDITAS MEDICINE, INC.2024-02-02Paul Joseph Wrighton | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on EDIT
Company overviewEverything on EDIT in one place, with the price.SEC filingsWhat EDIT's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat EDIT's own officers and directors buy and sell.Who owns itEvery manager reporting a position in EDIT.Funds holding itWhich funds and ETFs hold EDIT, and how big a bet.